Listen
Reason for request
Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.
-
Clinical Benefit
| Substantial |
The Actual Benefit of ZYPREXA and ZYPREXA VELOTAB in the treatment of schizophrenia remains substantial. |
Clinical Added Value
| moderate |
ZYPREXA and ZYPREXA VELOTAB, as with all other anti-psychotics (including first generation anti-psychotics), provide a moderate Improvement in Actual Benefit (IAB III) in the treatment of schizophrenia. |
Contact Us
Évaluation des médicaments
Français